Please login to the form below

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

New cancer drugs can’t quite plug the revenue hole at AZ

Other bright spots for AZ included the continued growth if antiplatelet drug Brilinta (ticagrelor), up 18% to $609m, diabetes drug Farxiga (dapagliflozin) which leaped 36% to $639m, and new asthma drug

Latest news

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

risk of lower-limb amputation in diabetics, putting it at a disadvantage compared to rival SGLT2 drugs such as Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) and AstraZeneca’s Farxiga
J&J says real-world data finds no amputation risk for Invokana

Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) has also continued to gather pace with the company reporting sales rose 29% to just over $1bn last year.
The year of the blockbuster

entrant to an increasingly crowded market and will compete directly with first-to-market Invokana, as well as Farxiga and Jardiance.
FDA starts review of Sanofi’s oral type 1 diabetes drug

Ingelheim's Jardiance and Farxiga from AstraZeneca.
AZ expects return to growth this year after 2017 decline

The contribution of these drugs as well as blockbuster sales for antiplatelet therapy Brilinta (ticagrelor) and diabetes drug Farxiga (dapagliflozin) allowed AZ to boost operating profit by 2% to $6.86bn

More from news
Approximately 4 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Manager: Negotiable

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Medical Writer - Creative and Scientific Projects: DOE

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Sudler London - Senior Medical Writer: Competitive

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Account Manager- 4 days per week or full-time: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Healthcare PR Senior Account Manager: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Associate Scientific Director: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Graduate Scientific Editor: DOE

Market Access Consultant - Greater Manchester: Negotiable

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director or Senior Account Director: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Director, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....